Short Interest in Amedisys, Inc. (NASDAQ:AMED) Decreases By 14.7%

Amedisys, Inc. (NASDAQ:AMED) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,210,000 shares, a drop of 14.7% from the November 30th total of 2,590,000 shares. Approximately 6.9% of the shares of the company are sold short. Based on an average daily volume of 539,400 shares, the days-to-cover ratio is currently 4.1 days.

Amedisys Trading Up 4.7 %

Amedisys stock traded up $4.01 during mid-day trading on Friday, hitting $89.96. 2,013,218 shares of the stock were exchanged, compared to its average volume of 389,869. The firm’s fifty day simple moving average is $90.45 and its two-hundred day simple moving average is $94.43. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of 35.70, a PEG ratio of 1.84 and a beta of 0.73. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The firm had revenue of $587.67 million during the quarter, compared to analysts’ expectations of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.98 earnings per share. Analysts forecast that Amedisys will post 4.45 EPS for the current year.

Institutional Trading of Amedisys

Several institutional investors and hedge funds have recently modified their holdings of AMED. Oddo BHF Asset Management Sas purchased a new stake in Amedisys in the third quarter valued at approximately $7,238,000. Barclays PLC increased its stake in shares of Amedisys by 49.5% during the third quarter. Barclays PLC now owns 15,529 shares of the health services provider’s stock valued at $1,500,000 after purchasing an additional 5,142 shares in the last quarter. Geode Capital Management LLC grew its position in Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after purchasing an additional 7,071 shares during the last quarter. National Bank of Canada FI lifted its position in Amedisys by 119.0% in the 3rd quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after acquiring an additional 30,213 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in Amedisys by 60.4% during the third quarter. Quantinno Capital Management LP now owns 40,457 shares of the health services provider’s stock valued at $3,905,000 after purchasing an additional 15,238 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.